GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: BIIB
Outperform

Biogen Idec Inc (NASDAQ: BIIB) rated to Outperform by Wells Fargo

Friday,  Dec 4, 2015  10:25 AM ET by Betsy O'Brien Harrison

Wells Fargo rated
Biogen Idec Inc (NASDAQ: BIIB) to Outperform.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy